Can the HPV vaccine stop precancer from returning? major trial launches
NCT ID NCT07431502
First seen Mar 08, 2026 · Last updated May 11, 2026 · Updated 12 times
Summary
This study tests whether the HPV vaccine can prevent the return of high-grade precancerous lesions in people who have already been treated for them. About 984 participants aged 18 to 55 with HPV-related lesions at various sites (cervix, vulva, vagina, penis, anus) will receive either the vaccine or a placebo. The goal is to see if vaccination reduces the chance of the same HPV type causing new lesions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PATIENTS WITH PRIMARY HPV HIGH-GRADE SQUAMOUS INTRA-EPITHELIAL LESIONS (HSIL) AT VULVAR SITE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.